e-FabRIC

e-FabRIC objectives: ➡️ Save lives with a treatment that addresses new emerging viruses within the Sabercovirus family ➡️ Demonstrate the potency of mosaic hyperimmunization ➡️ Produce a multivalent polyclonal antibodies therapy e-FabRIC is a European consortium coordinated by Fabentech with expert collaborators : University of Cambridge, Institute of Tropical Medicine Antwerp, Foundation for Biomedical Research of the Hospital Universitario 12 De Octubre in Madrid, BIOTEM First Class Antibodies & Immunoassays, and FIPRA Public Affairs. *** e-FaBRIC is a European consortium project that aimed at developing an innovative broad-spectrum antiviral therapy to combat new emerging infectious diseases with pandemic potential, particularly those caused by viruses in the Sarbecovirus family. e-FabRIC will develop a treatment based on a new hyperimmunization strategy for generating immunoglobulins having a broad neutralizing specificity against several virus of the same subfamily. Considered to be one of the riskiest virus, Sarbecovirus are responsible for severe respiratory pathologies in humans, coupled with a high mortality rate and strong mutagenic capabilities (1,2). 💪 Join us in the fight against emerging infectious diseases! 1. Severe Acute Respiratory Syndrome (SARS) (who.int) 2. Liu, B., Zhao, P., Xu, P. et al. A comprehensive dataset of animal-associated Sarbecoviruses. Sci Data 10, 681 (2023) HORIZON-HLTH-2023-DISEASE-03 / e-FabRIC – Number: 101137157 ____________________________________________________ Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.